ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Value Strategy” third quarter ...

Over the past 13 years, Baltimore spent at least $197 million — an average of more than $15 million a year — combating the raging opioid epidemic, an expert hired by the city testified in its civil ...

A Drug Enforcement Administration agent in October 2005 requested documents about drug distributor McKesson’s sale of opioids to an internet pharmacy in East Baltimore. In a March 2009 email to ...

Big pharmacies like Drug City ordered large quantities of opioids, he agreed, but they also bought large quantities of other ...

Improving the Patient Financial Experience Throughout the Patient Journey While many healthcare providers believe that improving the patient financial experience is a critical step for their ...

Given that McKesson Corporation (NYSE:MCK) is one of the biggest firms of its kind as it serves more than 2.1 million people, the firm can benefit from trends in the pharmacy industry. The biggest ...

In this article, we are going to take a look at where McKesson Corporation (NYSE:MCK) stands against the other Larry Robbins-approved stocks. Glenview Capital Management, founded in 2000 ...

McKesson launches InspiroGene by McKesson, a dedicated business focused solely on supporting the commercialization of cell ...

McKesson and Cabinet’s partnership leads ... to partner with the organization which continues to be a prominent pharmacy partner. Knox - In the realm of direct-to-consumer businesses, where ...

Shares of McKesson (MCK) are oversold. They are also at a potential support level. Stocks that are oversold and at support tend to rally. The best traders traders focus on key price levels and ...

West Virginia reached a $400 million settlement on Monday with opioid distributors AmerisourceBergen Drug Co., Cardinal Health Inc., and McKesson Corp. Regional pharmacy chain operator Giant Eagle ...

Taken together, the testimony of Ruth Carter, the former DEA agent, and Adam, showed that McKesson rarely declined to increase a pharmacy’s opioid threshold. In the case of one business ...